IBI 355
Alternative Names: IBI-355Latest Information Update: 28 Oct 2024
At a glance
- Originator Innovent Biologics
- Class
- Mechanism of Action CD40 ligand modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Sjogren's syndrome
Most Recent Events
- 23 Sep 2024 Innovent Biologics completes a phase I trial in Autoimmune disorders (In volunteers) in China (IV) (NCT06110338)
- 14 Jul 2024 Phase-I clinical trials in Sjogren's syndrome in China (IV) (NCT06484855)
- 03 Jul 2024 Innovent Biologics plans a phase I trial for Sjogren's syndrome in China(IV) in July 2024 (NCT06484855)